% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Elmadany:180794,
      author       = {N. Elmadany$^*$ and O. Alhalabi$^*$ and M. Platten$^*$ and
                      L. Bunse$^*$},
      title        = {{S}ite-{S}pecific {C}onsiderations on {E}ngineered {T}
                      {C}ells for {M}alignant {G}liomas.},
      journal      = {Biomedicines},
      volume       = {10},
      number       = {7},
      issn         = {2227-9059},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-01556},
      pages        = {1738},
      year         = {2022},
      note         = {#EA:D170#LA:D170# / HI-TRON},
      abstract     = {Immunotherapy has revolutionized cancer treatment. Despite
                      the recent advances in immunotherapeutic approaches for
                      several tumor entities, limited response has been observed
                      in malignant gliomas, including glioblastoma (GBM).
                      Conversely, one of the emerging immunotherapeutic modalities
                      is chimeric antigen receptors (CAR) T cell therapy, which
                      demonstrated promising clinical responses in other solid
                      tumors. Current pre-clinical and interventional clinical
                      studies suggest improved efficacy when CAR-T cells are
                      delivered locoregionally, rather than intravenously. In this
                      review, we summarize possible CAR-T cell administration
                      routes including locoregional therapy, systemic
                      administration with and without focused ultrasound, direct
                      intra-arterial drug delivery and nanoparticle-enhanced
                      delivery in glioma. Moreover, we discuss published as well
                      as ongoing and planned clinical trials involving CAR-T cell
                      therapy in malignant glioma. With increasing neoadjuvant
                      and/or adjuvant combinatorial immunotherapeutic concepts and
                      modalities with specific modes of action for malignant
                      glioma, selection of administration routes becomes
                      increasingly important.},
      subtyp        = {Review Article},
      keywords     = {CAR T cells (Other) / CARs (Other) / FUS (Other) /
                      glioblastoma (Other) / glioma (Other) / intrathecal delivery
                      (Other) / nanotechnology (Other) / systemic delivery
                      (Other)},
      cin          = {D170 / HD01 / B067},
      ddc          = {570},
      cid          = {I:(DE-He78)D170-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)B067-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35885047},
      doi          = {10.3390/biomedicines10071738},
      url          = {https://inrepo02.dkfz.de/record/180794},
}